working
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
sooner or later it will arrive
we have confirmed fdv in chart of 7 days 30 minutes
let's go up
NITE, like Monday trying to stop this,
We'll see if he gets it today
always putting the ASK below the last change
huge backlog here before attacking again previous highs
IPIX
0.32 hitting hard and falling
NITE doing everything it can to stop it
I Agree, NITE working hard
Hello friend, what a joy, how long
I left values below $ 0.1 (restriction, it is from the broker for foreigners)
and your question YES, IPIX I think it's going to be HUGE,
look DD is huge,
PH2 trials with humans have begun for a COVID19 therapy (no vaccine) to date there is no
I think we'll be dollars soon
even doing nothing, look at BABL
one more confirmation for the detractors, we continue to take steps forward,
It is indifferent when the study ends, April or June,
everything will be fine if the studies are positive,
meanwhile we will continue to hear the detractors,
but we are where we are and we continue to comply with what the PR say
21 days from the recruitment of the first human,
nobody knows when that date could have been,
According to the PR of the company, the "first week" of February would begin, but what a day ...
I even doubt that it is something so "mathematical", the Algasigma study is unpublished ...
I agree, but OTC is also where the biggest movements occur,
With these data it is incomprehensible that we are still at $ 0.28 and the effect of the news is only a few days
An example: CYDY, it is OTC too, it went from $ 0.29 to 8-10$, and so on many OTC
The behavior of the PPS is disappointing, I imagine that for everyone, but hey, we'll be here until we get results
HUGE POST:
The Peer Reviewed Article along with the Fast Track designation from the FDA validate the scientific value proposition of Brilacidin to treat CV19. This Peer Reviewed Article was finalized and published on 2/9/21. Peer reviews are an important validation of the science and the main audience for them are medical professionals.
The ultimate market validation will be the announcement of the success in the current B-CV19 human trial. A successful B-CV19 human trial will lead to immediate funding, EUA revenue and an accelerated and funded Phase 3. Up Listing should occur fairly quickly as investors discover this little known baby biotech company that is the COVID KILLER.
============================================
Innovation Pharmaceuticals Announces Publication of Peer-Reviewed Scientific Article in the Journal Viruses on the Anti-SARS-CoV-2 Properties of Brilacidin
• Emerging mutations to the coronavirus are unlikely to affect Brilacidin’s ability to inhibit the virus
• Brilacidin currently is being evaluated in a Phase 2 clinical trial in hospitalized COVID-19 patients
WAKEFIELD, MA – March 2, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced the publication of a peer-reviewed scientific article—Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture—in the journal Viruses.
The article is accessible at the link below.
• Bakovic, A.; Risner, K.; Bhalla, N. (et al). Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture. Viruses 2021, 13, 271; https://doi.org/10.3390/v13020271
https://www.mdpi.com/1999-4915/13/2/271/
In the paper, Brilacidin was shown to exert potent inhibitory effects on SARS-CoV-2 in cell culture by decreasing viral load in different cell types, including ACE2 positive human lung cells, and, importantly, in both the Washington and Italian strains of the coronavirus . Testing of Brilacidin against additional SARS-CoV-2 strains is planned.
Already with over a half-million deaths in the U.S. and over two million deaths worldwide attributable to COVID-19, the emergence of more transmissible and more virulent variants of the novel coronavirus is causing added concern. Last week, the U.S. FDA issued industry guidance outlining recommendations for developing vaccines, drugs and diagnostic tools based on variants.
Brilacidin’s ability to disrupt viral integrity suggests Brilacidin likely is not subject to resistance developing due to coronavirus variants—unlike current COVID-19 treatments , such as monoclonal antibodies and convalescent plasma, and first-generation COVID-19 vaccines. This mechanism of action supports Brilacidin as a clearly differentiated antiviral in clinical development.
Leo Ehrlich, Chief Executive Officer of Innovation Pharmaceuticals, commented, “Infectious disease experts have noted the next phase in the global fight against COVID-19 will be in developing potent antivirals that directly act on the SARS-CoV-2 virus—which is what Brilacidin has been shown to do in pre-clinical studies. The Company looks forward to continuing its scientific collaborations with government and academic researchers to further inform Brilacidin’s treatment potential as a broad-spectrum antiviral drug candidate targeting coronaviruses, regardless of mutation or strain.”
Currently, Brilacidin is being evaluated in a global Phase 2 clinical trial in hospitalized COVID-19 patients.
Brilacidin and COVID-19
Brilacidin, which has received FDA Fast Track designation for the potential treatment of COVID-19 , is one of the few drugs targeting COVID-19 that has been tested in human trials (a total of 8) for other clinical indications, providing established safety and efficacy data on over 460 subjects, thereby potentially enabling it to rapidly help address the novel coronavirus crisis. Pre-clinical testing at independent laboratories supports Brilacidin’s antiviral ability to safely and potently inhibit SARS-CoV-2, and multiple strains of human coronaviruses (H-CoVs). In a human lung cell line against SARS-CoV-2, Brilacidin achieved a Selectivity Index of 426. A molecular screening study of 11,552 compounds also supports Brilacidin as a promising novel coronavirus treatment. Brilacidin antiviral research to date has been limited to laboratory-based experiments. Additional pre-clinical and clinical data support Brilacidin’s inhibition of IL-6, IL-1ß, TNF-a and other pro-inflammatory cytokines and chemokines, which have been identified as central drivers in the worsening prognoses of hospitalized COVID-19 patients. Brilacidin’s robust antimicrobial properties might also help to fight secondary bacterial infections , which can co-present in up to 20 percent of COVID-19 patients. Collectively, these data support Brilacidin as a unique 3-in-1 combination—antiviral, immuno/anti-inflammatory, and antimicrobial—COVID-19 therapeutic candidate, with pan-coronavirus treatment potential. The Company has initiated a randomized, placebo-controlled Phase 2 clinical trial of Brilacidin for treatment of COVID-19 in moderate-to-severe hospitalized patients.
Global COVID-19 Cases and Mortality
An online tool tracking COVID-19 cases and mortality, both in the U.S. and globally, can be found on the Company’s website (http://www.ipharminc.com), and at the following link:
https://ipixcovid19tracker.com/
We have: positive data in human lung cells, we have fast-track designation from the FDA, confirmation of PH2 initiation with humans, publication in peer-reviewed scientific journal ...
Only one thing is missing: a clear, forceful price reaction
In my IMO, the Phase II results should not be essential for this price reaction
Just with this news we should be dollars
https://www.mdpi.com/1999-4915/13/2/271
maybe a partnership would be "necessary"?
http://www.ipharminc.com/press-release/2021/3/2/innovation-pharmaceuticals-announces-publication-of-peer-reviewed-scientific-article-in-the-journal-viruses-on-the-anti-sars-cov-2-properties-of-brilacidin
http://www.ipharminc.com/press-release/2021/2/26/innovation-pharma-provides-study-details-for-ongoing-phase-2-clinical-trial-of-brilacidin-in-hospitalized-covid-19-patients
LOOOLLLLL and 0.12, 0.14, 0.16.................
1.179.784 vol
ASK 0.34 --- 83.566 VOL
1.167.284 vol, 0.34$ falling
I Agree, 0.40$ are here
all our requests, against the detractors, have been fulfilled: success in lung cells, FDA's Fast Track Status, Peer review, PH2 start ...
I just needed the PPs to respond
all our requests, against the detractors, have been fulfilled: success in lung cells, FDA's Fast Track Status, Peer review, PH2 start ...
I just needed the PPs to respond
Brilacidin’s ability to disrupt viral integrity suggests Brilacidin likely is not subject to resistance developing due to coronavirus variants—unlike current COVID-19 treatments, such as monoclonal antibodies and convalescent plasma, and first-generation COVID-19 vaccines. This mechanism of action supports Brilacidin as a clearly differentiated antiviral in clinical development.
...Brilacidin currently is being evaluated in a Phase 2 clinical trial in hospitalized COVID-19 patients
http://clinicaltrialsregister.ru/search/index1.php?q=IPI-BRIc-201&s=
you can press on the "pill" "heart" "calendar" and the + sign to see all the information
sorry for you who have millions of shares
The shorts theme is the "excuse" of all message boards without exception,
they all resort to the same "shorts"
I believe that the tests take time, we look every day, every minute and we despair,
but it is also true that in the phase we are in is a very low PPS,
The regulations at 42 CFR 11.24(a) require that, for an applicable clinical trial for which registration information is required to be submitted, the registration information specified in section 402(j)(2)(A)(ii) of the PHS Act or 42 CFR 11.28(a) must be submitted within 21 days after the first human subject is enrolled. The final rule in 42 CFR 11.10(a) defines "enroll or enrolled" to mean a "human subject's, or their legally authorized representative's, agreement to participate in a clinical trial following completion of the informed consent process, as required in 21 CFR part 50 and/or 45 CFR part 46, as applicable." The definition further states that "for the purposes of … [42 CFR part 11], potential subjects who are screened for the purpose of determining eligibility for a trial, but do not participate in the trial, are not considered enrolled, unless otherwise specified by the protocol."
https://clinicaltrials.gov/ct2/manage-recs/faq#regInfoSubDeadline
https://clinicaltrials.gov/ct2/results?term=brilacidin
very soon it will be published here
very good LOL and the brick walls
that there is a brick wall at $ 0.08?
nonconformity, always going against,
10 minutes ago we wanted to know if the study with humans had really started
WE ALREADY KNOW
They are running out of excuses.
When the results are published,
What will they look for?
Make yourselves to the idea: human trials are underway and in due course we will have results
Now detractors will look for other excuses.
Human study has begun!
It will be published soon and they can give it whatever laps they want, it is reality even if they do not like it
WATCH OUT FOR THE NEXT DAYS: https://clinicaltrials.gov/ct2/results?term=brilacidin
enough for the unbelievers:
1st study started
2nd is in process
3rd will be published imminently
Why would you anticipate publication if the results were bad?
I tell you: the results are good
many said that he had not even eaten:
well he has started
It is in process
and will be published imminently
IT'S CLEAR: the study has started and will be published at www.clinicaltrials.gov.,
I, if the preliminary results were bad, I would not be in a hurry to advance anything
HAVE YOUR BETS
When must I submit the required clinical trial registration information?
The regulations at 42 CFR 11.24(a) require that, for an applicable clinical trial for which registration information is required to be submitted, the registration information specified in section 402(j)(2)(A)(ii) of the PHS Act or 42 CFR 11.28(a) must be submitted within 21 days after the first human subject is enrolled. The final rule in 42 CFR 11.10(a) defines "enroll or enrolled" to mean a "human subject's, or their legally authorized representative's, agreement to participate in a clinical trial following completion of the informed consent process, as required in 21 CFR part 50 and/or 45 CFR part 46, as applicable." The definition further states that "for the purposes of … [42 CFR part 11], potential subjects who are screened for the purpose of determining eligibility for a trial, but do not participate in the trial, are not considered enrolled, unless otherwise specified by the protocol."
https://clinicaltrials.gov/ct2/manage-recs/faq#regInfoSubDeadline
Now the question is: when did the first human sign up?
WAKEFIELD, MA - January 29, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB: IPIX) (“the Company”), a clinical stage biopharmaceutical company, announces today that the Company's Phase 2 clinical trial of Brilacidin for treating COVID-19 is scheduled to begin next week.
http://www.ipharminc.com/press-release/2021/1/29/innovation-pharmaceuticals-phase-2-clinical-trial-of-brilacidin-for-treating-covid-19-scheduled-to-begin- next-week
Well with these data, let's get numbers, let's count up to 21